Test introduction Detection advantage Testing process For people
Technical brief

About the technology

1. What is individualized medication guide for cancer treatment?

Individualized medication for cancer treatment refers to the provision of more targeted drug regimens for patients according to their gene test results and pharmacogenetic mechanisms, in an effort to improve the effectiveness of treatment and maximizepatients’ lifespan.


Studies show that certain gene variation is directly related to the effect of cancer drugs. That also explains why patients who have the same cancer and administer the same drug show vastly different therapeutic effect or toxic and side effect. As manifested by clinical practices, common cancer drugs are only 25% effective.


Individualized administration of cancer drugs improve the effective rate of the drugs by 75% or higher. Therefore, individualized medication is an optimal choice for both doctors and cancer patients.


2. Scope of test

Gene test targeted at 16 types of chemotherapy/targeted drugs for high-incidence cancers in China.  

 

Medical cases

1. Clinical application of chemotherapy drug gene test

1460624335541665.png

As inhibitor I of DNA topoisomerase, irinotecan disables recombination of broken DNA single strand, and prevents DNA replication and RNA synthesis, causing cell death. Studies show that the polymorphism of UGT1A1 promoter region is correlated with the toxic effect of irinotecan. If irinotecan is used without instructions, neutropenia and diarrhea occur.


According to clinical experiments, patients experience low toxic and side effects after taking irinotecan if their UGT1A1 is of wild type. However, toxic and side effects from irinotecan are remarkably increased for the patient whose UGT1A1 is of mutant type.


2.  Clinical application of targeted drug gene test


   1460624174597062.png

As pointed out by NCCN (National Comprehensive Cancer Network) 2010 Cancer Treatment Guidelines, EGFR mutation, particularly exon 19 deletion mutation and exon 21 mutation, is significantly associated with the sensitivity of tumor treatment by EGFR-TKI drugs (such as gefitinib and erlotinib).


Clinical experiments indicate that when used for treating non-small cell lung cancer, such targeted drugs as gefitinib achieve an effective rate of 71.2% for patients with EGFR mutation, which is higher than the effective rate of traditional chemotherapy regimens: 47.3%. However, the drugs are only 1.1% effective for patients without EGFR mutation. If a patient is not sensitive to targeted drugs, it is better to adopt traditional chemotherapy solutions. This shows the importance of targeted drug gene test in clinical application.


Significance of the test

1. Helping clinical doctors set individualized medication solutions for different patients;

2. Helping comprehensively and accurately predict the effect of drugs and evaluate risks of drugs;

3. Helping predict the effect of multiple drugs at one time and avoid the insufficiency of single drug test.


Technical advantages

1460623968373295.png


Testing process

1460623905465209.png


For people

1. Cancer patients on their first visit to hospitals for treatment and with hope to obtain the optimal medication solutions.

2. Cancer patients whose drug regimens failed to achieve good therapeutic effect and who wish to use better drug regimens.

3. Cancer patients with ineffective existing drug regimens, cancer recurrence or metastasis, and the need to reset drug regimens.


Copyright © Annoroad Gene Technology 京ICP备12029022号-1